Your Cart
Your Cart is Empty
Insilico Medicine
Insilico Enters Into Research Collaboration with Pfizer Inc.
Insilico Medicine, a Juvenescence partner, enters into research collaboration with Pfizer Inc. to utilize Insilico’s machine learning technology to identify evidence for potential therapeutic targets implicated in a variety of diseases.
January 14, 2020
Read MoreJuvenescence
Extension of NetraMark’s NetraPharma Collaboration with Juvenescence
NetraMark Corp. and Juvenescence are excited to announce the extension of their collaboration agreement to include drug repurposing and drug discovery.
December 10, 2019
Read MoreAgeX Therapeutics
AgeX Therapeutics Issues Year-End Letter to Shareholders
At the end of its first year as a public company, Juvenescence partner AgeX issues a letter shareholders reflecting on progress made, as well as current initiatives and future plans.
December 9, 2019
Read MoreAgeX Therapeutics
AgeX Therapeutics and Juvenescence Publish Engineering Strategies for Universal Cells
AgeX Therapeutics, a biotechnology company, and Juvenescence, a biotech longevity company, announce the publication of a new paper in the peer-reviewed scientific journal Regenerative Medicine.
October 30, 2019
Read MoreLyGenesis
LyGenesis Closes $4 Million Convertible Debt Financing to Begin Clinical Development of Liver Regeneration Technology
LyGenesis, a Juvenescence partner, focused on organ regeneration, announced that they have completed a total of $4 million in private financing of convertible notes from Juvenescence, and the Longevity Vision Fund.
October 21, 2019
Read MoreInsilico Medicine
Insilico Medicine secures $37M in Series B funding led by Qiming Venture Partners
Insilico Medicine, a next generation AI technology and Juvenescence partner, completes $37 million Series B funding that will be used to commercialize the validated generative chemistry and target identification technology.
September 10, 2019
Read MoreInsilico Medicine
Insilico Medicine Develops and Validates Powerful AI System To Transform Drug Discovery
Insilico Medicine has developed GENTRL, a new artificial intelligence system for drug discovery that dramatically accelerates the process from years to days.
September 2, 2019
Read MoreAgeX Therapeutics
AgeX Therapeutics publishes Theoretical Basis of Human Cell-Age Reversal in the Journal of Regenerative Medicine
AgeX Therapeutics, a Juvenescence biotechnology company focused on therapeutics for human aging and regeneration, announced today, the theoretical foundation of the Company’s induced Tissue Regeneration (iTRTM) technology.
August 28, 2019
Read MoreJuvenescence
Juvenescence closes $100 Million Series B Round
Juvenescence, a life sciences company utilizing expert drug developers and artificial intelligence experts to create therapeutics and technologies to treat diseases of aging and to increase human longevity.
August 19, 2019
Read MoreJuvenescence
Juvenescence appoints Colin Watts as CEO of Juvenescence Life
Juvenescence announces that Colin Watts has joined its Management Team as CEO of Juvenescence Life. Driving Human longevity and quality of life.
July 11, 2019
Read MoreJuvenescence
Juvenescence Confirms Close of Souvien Therapeutics and Announces High-level Appointments
Juvenescence is pleased to announce its latest biotech company Souvien Therapeutics (“Souvien”), creating innovative medicines to address neurodegenerative diseases by targeting the epigenetic underpinnings of neurodegeneration.
May 28, 2019
Read MoreJuvenescence
Juvenescence Announces the Appointment of David Ellam as Chief Financial Officer
Juvenescence announces that David Ellam has joined its Executive Management Team as Chief Financial Officer.
April 24, 2019
Read MoreJuvenescence
Juvenescence Capitalizes BYOMass
Juvenescence is pleased to announce its latest equity investment in BYOMass, a Massachusetts-based company focused on central control of metabolism in the context of aging and age-related diseases.
March 27, 2019
Read MoreBHB Therapeutics
Juvenescence and the Buck Institute launch BHB Therapeutics
Juvenescence and the Buck Institute for Research on Aging announce a new collaboration with the formation of BHB Therapeutics a joint venture.
February 4, 2019
Read MoreJuvenescence
Juvenescence closes First $46M Tranche of $100M Series B
Juvenescence is pleased to announce the close of the first tranche of its Series B financing, in the amount of $46 million.
January 16, 2019
Read More
Contact Us
We are here to help answer any questions you might have.
